Apogee meets trial endpoints
Apogee's zumilokibart shows promise in treating dermatitis, meeting Phase 2 trial endpoints. This may impact the company's stock and the biotech sector.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.